Business
Cooper is a global medical device company with two operating businesses: CooperVision contact lenses and myopia-management products, and CooperSurgical fertility and women's health products and services.
Cooper grew revenue +5.1% and FCF +50.5%, while margins compressed and insiders bought.
The read at a glance✓ Audited against SEC data
- Growth — Revenue +5.1% to $4.09BOK
- Profitability — Net income -4.4% to $0.37BWatch
- Cash quality — FCF +50.5% to $0.43BOK
- Margins — Gross -110 bps; operating margin -143 bpsWatch
- Balance sheet — Debt -3.6% to $2.46BOK
- Insiders — 10 buys / 0 sellsOK
Where the revenue comes from
Fiscal 2025, as COOPER COMPANIES, INC. reports it. History and quarterly detail are in the app.
- Sphere, other$1.4B
- Toric and multifocal$1.4B
- Office and surgical$824.0M
- Fertility$524.6M
Leadership changes
From COOPER COMPANIES, INC.'s own filings, the day they're filed.
- Paul Keel · director · departureeff. 2026-07-01
- Brian G. Andrews · Chief Financial Officer · appointmenteff. 2025-12-09
- Agostino Ricupati · President · appointment
Latest filings
- 10-Q · Quarterly report2026-06-05
- 8-K · Company announcement2026-06-04
- 8-K · Company announcement2026-05-04
- 8-K · Company announcement2026-04-08
- 10-Q · Quarterly report2026-03-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about COOPER COMPANIES, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.